Onkológia 5/2009

Temsirolimus – mTOR as a new target for the treatmet of advanced cell carcinoma (RCC) and relapsed and/or refractory mantle cell lymphoma (MCL)

Temsirolimus is a selective inhibitor of mTOR (mammalian target of rapamycin). Temsirolimus binds to an intracellular protein FKBP-12, and the protein/temsirolimus complex binds and inhibits the activity of mTOR that controls cell division. The anti-tumour effect of temsirolimus may also in part stem from its ability to selective disrupt translation of cell cycle regulatory proteins and to inhibit angiogenesis. Temsirolimus is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC) who have at least three of six prognostic risk factors and for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (MCL).

Keywords: temsirolimus, mTOR inhibitor, advanced renal cell carcinoma (RCC) – refractory mantle cell lymphoma (MCL)